Sangamo Therapeutics Inc (NASDAQ:SGMO) price closed lower on Tuesday, July 01, and dropping -0.94% below its previous close.
A look at the daily price movement shows that the last close reads $0.54, with intraday deals fluctuated between $0.5118 and $0.55. The company’s 5Y monthly beta was ticking 1.21. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.18 and 52-week low of $0.30. The stock added 15.31% on its value in the past month.
Sangamo Therapeutics Inc, which has a market valuation of $131.59 million, is expected to release its quarterly earnings report on 2025-May-12.
On average, analysts have forecast the company’s revenue for the quarter will hit 31.68M, with the likely lows of 400k and highs of 100M. The average estimate suggests sales growth for the quarter will likely rise by 8,798.88% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of 57.68M for the company’s annual revenue in current year. Per this projection, the revenue is forecast to grow -0.21% below that which the company brought in the current year earning report.
Technical indicators in stocks provide crucial insights into market trends, guiding investors with precise entry and exit points based on price movements for informed decision-making.On the technical perspective front, indicators give SGMO a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 3 analysts have assigned SGMO a recommendation rating as follows: 2 rate it as a Hold; 1 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Sangamo Therapeutics Inc (SGMO) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Hold, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that SGMO’s price is at present 5.26% off the SMA20 and -5.91% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 51.54, with weekly volatility standing at 10.55%. The indicator jumps to 9.89% when calculated based on the past 30 days. Sangamo Therapeutics Inc (NASDAQ:SGMO)’s beta value is holding at 1.24. Considering analysts have assigned the stock a price target range of $2-$19 as the low and high respectively, we find the trailing 12-month average consensus price target to be $4. Based on this estimate, we see that current price is roughly -270.37% off the estimated low and -3418.52% off the forecast high. Investors will no doubt be excited to see the share price fall to $4, which is the median consensus price, and at that level SGMO would be -640.74% from current price.
An analysis of the Sangamo Therapeutics Inc (NASDAQ:SGMO) stock in terms of its daily trading volume indicates that the 3-month average is 7.13 million. However, this figure increases on the past 10-day timeline to an average of 6.98 million.
Current records show that the company has 245.40M in outstanding shares. The insiders’ percentage holdings are 3.16% of outstanding shares while the percentage share held by institutions stands at 21.61%. The stats also highlight that short interest as of 2025-06-13, stood at 25.67 million shares, which puts the short ratio at the time at 5.16. From this we can glean that short interest is 1057.00 of company’s current outstanding shares. Notably, we see that shares short in June fall slightly given the previous month’s figure stood at 31.91 million. But the 34.52% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
